Skillings-Mack and Wilcoxon signed-rank test (with Bonferroni adjustment) for FOXP3 data (see Table 2).

<p>Skillings-Mack and Wilcoxon signed-rank test (with Bonferroni adjustment) for FOXP3 data (see <a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0039368#pone-0039368-t002" target="_blank">Table 2</a>).</p

Summary of the dose escalation trial. 1 dose unit = 1×10⁷ DC.

<p> <i>(√ = 1 dose unit infused via i.v route and  = 1 dose unit infused via i.d route).</i></p><p> <i>(Adapted from Gowans et al. (2010) J Hepatol; 53:599).</i></p

T cells expressing FOXP3.

<p>(<b>A</b>) Example of plots showing gate settings. (<b>B</b>) The frequency of FOXP3⁺ T cells at different time points, gating on CD3⁺ T cells. (<b>C</b>) Inverse correlation between the frequencies of FOXP3⁺ Treg and CEF-specific TNFα/IFNγ dual functional T cells.</p

Gating strategy and example of ICS data.

<p>(<b>A</b>) Lymphocytes were gated based on FSC and SSC, followed by a CD3⁺ViViD⁻ viable T cell gate. (<b>B</b>) Example of data from PT#3, depicting typical positive (6×CTL, core antigen) and negative (E1E2 antigen) responses following DC infusion compared to baseline. (<b>C</b>) These plots are derived from the same data as the core antigen response at week 2 (W2), depicting the cellular source of the cytokines. The 1^st plot (left) shows cytokine positive cells (red) within viable CD3 T cells (grey), the 2^nd plot shows the position of the CD4⁺ and CD8⁺ T cell gates, and the 3^rd and 4^th plots depict the cytokine staining profiles of CD4⁺ T cells and CD8⁺ T cells respectively.</p

Cytokine positive responses - a complete dataset from all patients.

<p>(<b>A</b>) Cytokine producer frequency (%, gating on viable CD3⁺ T cells) at baseline and different time points thereafter. The numbers on the x-axis (1, 2, 3, 4, 5 and 6) are the patient ID. Abbreviations: BL = Base Line; PI-2 = Prior to 2^nd Infusion; PI-3 = Prior to 3^rd Infusion, W = Week post final infusion. (<b>B</b>) The normalised MFI, corresponding to the responses detected in (A). (<b>C</b>) T cell quality in PT#4 and PT#5, depicted by the normalised MFI of cytokine positive responses. (<b>D</b>) The frequency (%) and normalised MFI over time in PT#3. (<b>E</b>) The dose and timing of DC infusion each patient received and the timing of sample collection. (<b>F</b>) Contribution of CD4 and CD8 T cells (please note the differences in scale) to the cytokine positive responses in PT#3.</p

The frequency (% within CD3⁺ T cells) of FOXP3⁺ Treg of the patients at various time points.

<p>The frequency (% within CD3⁺ T cells) of FOXP3⁺ Treg of the patients at various time points.</p